ANAPC4

Across TCGA pan-cancer cohorts, ANAPC4 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ANAPC4 data layer compared with 23 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher ANAPC4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ANAPC4 expression acts as an unfavorable survival marker.

ESCA, UCEC, and SKCM are the cancer types where ANAPC4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	II,III,IV	0.136	0.703	<.001	24	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	DFS	Median	IV	0.040	0.454	.028	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ANAPC4–ESCA (OS)

Open the ESCA breakdown →